The team, led by Dr. François Bénard, has extensive experience in the pre-clinical development of radiotracers for PET/CT imaging, their translation to the clinic, and clinical trial design/execution. They have developed several new radiopharmaceuticals targeting tumour receptors, notably peptides and small molecule ligands. Dr. Bénard initiated the program that developed cyclotron production of 99mTc, now in clinical trials at multiple sites in Canada. A state-of-the-art cyclotron and molecular imaging facility was also established at BC Cancer. Current projects relate to the development of new radiopharmaceuticals to image receptors and enzymes overexpressed in breast and prostate cancers, as well as to new isotope production methods.
BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.